New drug SKB445 enters human testing for Hard-to-Treat cancers
NCT ID NCT06826040
First seen Jan 06, 2026 · Last updated Jun 11, 2026 · Updated 25 times
Summary
This early-phase study tests an experimental drug, SKB445, in 126 adults with advanced solid tumors that have not responded to or are not eligible for standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also watch for any signs that the drug shrinks tumors or slows cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.